Showing 6681-6690 of 8198 results for "".
- Experts Call for Greater Attention to Persistent Redness of Rosaceahttps://practicaldermatology.com/news/experts-call-for-greater-attention-to-persistent-redness-of-rosacea/2460896/Dermatologists should place greater emphasis on persistent facial erythema of rosacea, a panel of experts concludes. Their recommendations, based on a National Rosacea Society (NRS) roundtable conversation, appear in the <
- Lilly's Lebrikizumab Performs Well in Two Phase 3 AD Trialshttps://practicaldermatology.com/news/lillys-lebrikizumab-performs-well-in-two-phase-3-ad-trials/2460892/Eli Lilly and Company's lebrikizumab led to significant improvements with at least 75 percent skin clearance in more than half of people with moderate-to-severe atopic dermatitis (AD), according to top-line results from ADvocate 1 and ADvocate 2. All primary and all key secondary en
- New Gel Shows Promise Against BCChttps://practicaldermatology.com/news/new-gel-shows-promise-against-bcc/2460890/Medivir AB’s topical histone deacetylase (HDAC) inhibitor remetinostat performed well in a phase II study in basal cell carcinoma (BCC), according to research published online in Clinical Cancer Research. The new gel could reduce the need for surgical
- Open-label Extension Study Shows Long-term Safety, Efficacy for UCB's Bimekizumab in PsOhttps://practicaldermatology.com/news/open-label-extension-study-shows-long-term-safety-efficacy-for-ucbs-bimekizumab-in-pso/2460883/New interim data from an open-label extension trial to assess the long-term safety, tolerability, and efficacy of bimekizumab show that the majority of patients who achieved complete or near complete skin clearance after 16 weeks of bimekizumab treatment maintained these responses through to
- Strand Therapeutics Scores Two Grants to Advance Programmable, Long-Lasting mRNA Therapeutics for Melanoma and Breast Cancerhttps://practicaldermatology.com/news/strand-therapeutics-scores-two-grants-to-advance-programmable-long-lasting-mrna-therapeutics-for-melanoma-and-breast-cancer/2460881/Strand Therapeutics was awarded two Phase I Small Business Innovation Research (SBIR) grants from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to develop mRNA-based therapeutics for melanoma and triple negative breast cancer (TNBC). The total fund
- ParaPRO’s Natroba for Scabies Now Availablehttps://practicaldermatology.com/news/parapros-natroba-for-scabies-now-available/2460877/ParaPRO’s Natroba (spinosad) Topical Suspension, 0.9% for scabies is now available. Natroba is the first new scabies drug to be approved by the U.S. Food and Drug Administration (FDA) in more than 30 years. Earlier this year, the company received FDA approval of its supp
- US FDA Approves Saphnelo for Lupushttps://practicaldermatology.com/news/us-fda-approves-saphnelo-for-lupus/2460876/The U.S. Food and Drug Administration (FDA) approved Saphnelo (anifrolumab-fnia) as a treatment for adults with systemic lupus erythematosus (SLE) who are receiving standard therapy. Developed by AstraZeneca, Saphnelo is a monoclonal antibody administered by intravenous (IV)
- FDA Approves of Sol Gel's Twyneo for Acnehttps://practicaldermatology.com/news/fda-approves-of-sol-gels-twyneo-for-acne/2460874/The FDA has approved Sol Ge's first proprietary drug product, TWYNEO (tretinoin/benzoyl peroxide) cream, 0.1%/3%, for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older. TWYNEO uses Sol-Gel’s patented technology to entrap tretinoin, a retinoid, a
- Allergan Aesthetics Continues Partnership with Girls Inc.https://practicaldermatology.com/news/allergan-aesthetics-continues-partnership-with-girls-inc/2460869/Allergan Aesthetics is starting its third consecutive year of partnership with Girls Inc. and debuting Empowering Confidence Workshops, a nationwide mentoring initiative. Based on a 2020 Girls Inc. report, many girls have a hard time picturing themselves in science, technology, eng
- LiVDerm Brings SBS Part II to Hollywood, FL this Fallhttps://practicaldermatology.com/news/livderm-brings-sbs-part-ii-to-hollywood-fl-this-fall/2460868/SBS Part II: The Aesthetic Dermatology Summit comes to Hollywood, FL, September 23-25, closing out the two-part 19th Annual South Beach Symposium. Produced by LiVDerm, the event is centered on the latest and most re